The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)
Open accessAbstract
Clinical trials that compare strategies to optimize antibiotic use are of critical importance but are limited by competing risks that distort outcome interpretation, complexities of noninferiority trials, large sample sizes, and inadequate evaluation of benefits and harms at the patient level. The Antibacterial Resistance Leadership Group strives to overcome these challenges through innovative trial design. Response adjusted for duration of antibiotic risk (RADAR) is a novel methodology utilizing a superiority design and a 2-step process: (1) categorizing patients into an overall clinical outcome (based on benefits and harms), and (2) ranking patients with respect to a desirability of outcome ranking (DOOR). DOORs are constructed by assigning higher ranks to patients with (1) better overall clinical outcomes and (2) shorter durations of antibiotic use for similar overall clinical outcomes. DOOR distributions are compared between antibiotic use strategies. The probability that a randomly selected patient will have a better DOOR if assigned to the new strategy is estimated. DOOR/RADAR represents a new paradigm in assessing the risks and benefits of new strategies to optimize antibiotic use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
“Collateral Damage” from Cephalosporin or Quinolone Antibiotic Therapy
Paterson, D. L. (2004) · Clinical Infectious Diseases · doi:10.1086/382690 · Cited by 466
The clinical consequences of antimicrobial resistance
Rice, L. B. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.08.001 · Cited by 291
Snapinn, S. M. (2000) · Trials · doi:10.1186/cvm-1-1-019 · Cited by 267
Sample Size Determination for Some Common Nonparametric Tests
Noether, G. E. (1987) · Journal of the American Statistical Association · doi:10.2307/2289477 · Cited by 225
Current issues in non‐inferiority trials
Fleming, T. R. (2008) · Statistics in Medicine · doi:10.1002/sim.2855 · Cited by 211
Cosgrove, S. E., Seo, S. K., Bolon, M. K., Sepkowitz, K. A., Climo, M. W., Diekema, D. J., Speck, K. A., Gunaseelan, V., Noskin, G. A., Herwaldt, L. A., et al. (2012) · Infection Control and Hospital Epidemiology · doi:10.1086/664771 · Cited by 98
Self-citationPeron, E. P., Hirsch, A., Jury, L. A., Jump, R., & Donskey, C. J. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12099 · Cited by 87
Scientific and Ethical Issues in Equivalence Trials
Djulbegović, B. (2001) · JAMA · doi:10.1001/jama.285.9.1206 · Cited by 79
Noninferiority and equivalence trials: deciphering ‘similarity’ of medical interventions
Powers, J. H. (2008) · Statistics in Medicine · doi:10.1002/sim.3138 · Cited by 41
Self-citationOczkowski, S. J. W. (2014) · PubMed Central · Cited by 23
Cited by
van Duin, D., Lok, J. J., Earley, M., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Doi, Y., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix783 · Cited by 655
Self-citationYahav, D., Franceschini, E., Koppel, F., Turjeman, A., Babich, T., Bitterman, R., Neuberger, A., Ghanem-Zoubi, N., Santoro, A., Eliakim-Raz, N., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1054 · Cited by 433
Wang, M., Earley, M., Chen, L., Hanson, B. M., Yu, Y., Liu, Z., Salcedo, S., Cober, E., Li, L., Kanj, S. S., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00399-6 · Cited by 363
Self-citationvan Duin, D., Arias, C. A., Komarow, L., Chen, L., Hanson, B. M., Weston, G., Cober, E., Garner, O. B., Jacob, J. T., Satlin, M. J., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30755-8 · Cited by 337
Self-citationReyes, J., Komarow, L., Chen, L., Ge, L., Hanson, B. M., Cober, E., Herc, E., Alenazi, T., Kaye, K. S., Garcia-Diaz, J., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00329-9 · Cited by 321
Self-citation
Metadata
- Authors
- Evans, S. R., Rubin, D., Follmann, D., Pennello, G., Huskins, W. C., Powers, J. H., Schoenfeld, D., Chuang-Stein, C., Cosgrove, S. E., Fowler, V. G., Lautenbach, E., & Chambers, H. F.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-06-25
- Volume
- 61
- Issue
- 5
- Pages
- 800-806
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1933023737
- Cited by
- 361
- References
- 13
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). https://app.cochat.ai/papers/10.1093/cid/civ495
- The paper
- Evans, S. R., Rubin, D., Follmann, D., Pennello, G., Huskins, W. C., Powers, J. H., Schoenfeld, D., Chuang-Stein, C., Cosgrove, S. E., Fowler, V. G., Lautenbach, E., & Chambers, H. F. (2015). Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clinical Infectious Diseases. https://doi.org/10.1093/cid/civ495
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.